Self-Assembled Berberine-Sinapic Acid Nanomedicine for Synergistic Chemotherapy

    February 2026 in “ Molecules ”
    Ying Zhao, Yubo Lu, Yushan Ma, Sijia Wang, Pin Lv, Lulu Xu, Yuanyuan Li, Weisheng FENG
    Image
    Studysummary This study reported that a novel nanomedicine combining berberine and sinapic acid significantly inhibited the growth of mouse mammary carcinoma cells and demonstrated an anti-tumor effect in vivo, without significant systemic toxicity after 28 days, suggesting a promising, low-toxicity therapeutic strategy for breast cancer. Our plain-language summary of this paper — not a Tressless recommendation.
    The study introduces a novel nanomedicine, BBR-SA, formed by the self-assembly of berberine and sinapic acid, designed for synergistic chemotherapy against breast cancer. Utilizing π-π stacking, hydrogen bonding, and electrostatic forces, BBR-SA exhibits high drug-loading capacity and excellent water dispersibility. In a murine model with 40 mice, BBR-SA significantly inhibited tumor growth and enhanced therapeutic efficacy compared to berberine or sinapic acid alone, without causing significant systemic toxicity after 28 days of treatment. These findings suggest BBR-SA as a safe, effective, and biocompatible strategy for breast cancer treatment, highlighting its potential to overcome drug resistance and improve therapeutic outcomes.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results